01.09.24 -- Optimizing AAV Production: Key Areas For Enhanced Efficiency

Examine open small format tubing in cell and gene therapy labs and what technologies are on the horizon to help make more sterile connections going forward.

Explore the vital role that laminar airflow technology plays in meeting sterile integrity standards and minimizing contamination risks in pharmaceutical cleanrooms.

Review experiments that characterize the basic operating conditions of mammalian cultures in single-use bioreactors and parameters to be used when transferring cultures to/from other bioreactor systems.

Discover the significance of minimizing particulate levels for maintaining the purity of single-use systems and their potential impact on biomanufacturing, storage, and transportation of high-value final products.

See how enhanced T cell expansion – as well as the generation of an early-differentiated phenotype – can be achieved using a cell culture medium for T cells and cytokines in a static bioreactor system.

Single-use technology is vital for ensuring the quality and expedited market entry of genomic medicines. Learn how LNP technology is paving the way for a new era of personalized precise medicine.

Production of pure therapeutic DNA ONs requires efficient, scalable, and cost-effective chromatographic purification methods. This study tests a chromatography and resin pairing to determine its effectiveness.

Here, the authors demonstrate the ability of animal component-free Insti CHO and HEK cell culture supplements to overcome cell culture limitations while meeting regulatory requirements.

Uncover how the knowledge generated by a deep and thorough analysis of chemokine receptors on natural killer (NK) cells can be helpful to scientists studying certain cancers and diseases.

In a recent internal study, Waisman Biomanufacturing was able to demonstrate comparability for a new manufacturing platform combining bioreactors and microcarriers using mesenchymal stromal cells.

ElevateBio, in collaboration with Cytiva, is forging a path forward with a solution to de-risk the development of novel therapies, helping to speed the delivery of new CGTs and regenerative medicines.